EANM Oncology Committee

EANM Oncology Committee This is a committee under the umbrella organisation of the European Association of Nuclear Medicine (2) For this guideline the following terminology applies:
a.

GUIDELINES FOR THE ACCURATE USAGE OF SOCIAL MEDIA
Scope of application:
(1) This guideline regulates the usage of social media sites of the European Association of Nuclear Medicine ("EANM"). "Social Media": Social Media platforms (f.e. facebook, Google+, XING, linked-in), internet news services, portals for distribution of user generated content (f.e. youtube, vimeo) and all comparable web based s

ervices (f.e. blogs, forums, microblogging). b. "User": Members of the EANM, including its organs, employees, authorised representatives, contractors or others, related to the EANM or its members, as far as these utilise social media. c. "Utilisation" in the representational sense incorporates the utilisation of social media, i.e. the registration on a social media platform and the creation of an account and/or profile and/or site as well as the upload of pictures, movies, the posting of news or comments on EANM contents. d. "EANM-contents": The usage of social media in the name of or in reference to the EANM or in any other way, which creates a connection between released contents and the EANM or seem to be attributable to the EANM (i.e. by using the logo, CI etc.). Contents and disclaimer
(1) With the use of social media in a adequate way, it hast o be pointed out:
• EANM does not accept responsibility for the correctness, integrity, up-to-dateness and quality of the provided content. The utilisation and the allocation of contents are at the user’s own risk. Contributions identified by name do not necessarily represent the opinion of the EANM but the author’s opinion.
• EANM does not accept responsibility or liability for damages resulting from the use or disuse of information provided on social media. (2) EANM reserves the right to admonish users to change or amend parts or complete releases or to end or ban releases or users if these/those are not in accordance with this guideline. External links
(1) In the event of cross linking from social media with EANM content to third-party websites (external links), it is mandatory to indicate at the appropriate location, that (i) the respective providers are responsible for these websites, (ii) the user has screened the contents with the first time connection and could not recognise any obvious statutory violations and (iii) EANM has no influence on the current or future layout or content of the external link. User responsibilities
(1) As user of social media with EANM contents, users commit themselves not to post articles or comments, which violate these guidelines, public moral or applicable law. As user you furthermore accept the ethically correct usage of social media and you are specifically prohibited to:
• To publicise offending or incorrect contents; each user is responsible on its own for contents,
he/she publishes in social media. Since such contents are available over years and can be easily assigned to the author, respect and courtesy shall be in your own interest and also in the interest of EANM as bases for communication in any kind. Before publicising contents it is recommended to screen those towards possible lacks of clarity, usage of protected content and in particular referring to copyright and trademark;
• carry out competitive-contrary actions;
• launch advertisement of any kind (f.e. medical products, machines, conference or meetings announcements and others) without permission of the EANM. This also applies for surreptitious advertising, cross linking with own or fan-pages. (2) EANM reserves the right to delete postings or comments if those violate public moral, these guidelines or applicable law. (3) Users agree to review their posts and comments before publishing, whether they contain information they do not wish to publicise. Posts and topics can be listed in search engines and thus accessible worldwide. For information: A claim for cancellation or correction of such entries to the search engine provider is excluded. (4) Should third parties or other users claim EANM for possible violations of law, which a) result from the EANM content posted by users and/or b) arising from the use of social media with EANM content by users, such users are obliged to free the provider from any claims, including claims for damages, to hold EANM harmless and indemnify and to replace the cost which may arise due to the possible violation of the law. This affects in particularly, but not exclusively, the cost of the necessary legal representation of the EANM. Users are obliged to support EANM in good faith with information and documents in a legal defense against third parties. All other rights, including damage claims by EANM remain unaffected. Use of trademark / third-party content
(1) EANM reserves the right also to prohibit the use of trademarks, logos and other protected labels for the benefit of EANM, especially when usage threatens to harm or damage of the reputation of EANM or has already occurred. (2) Contents and rights of third parties are marked as such. The unauthorized reproduction or distribution of individual contents or complete pages is not allowed and punishable. Only the production of copies and downloads for personal, private and non-commercial use is permitted. (3) For the representation of web pages with EANM content in third-party frames the written permission of EANM required. Additional regulations
(1) EANM reserves the right to modify these guidelines at any time. (2) The general terms and conditions of the respective social media, which are to be observed also, remain unaffected by these guidelines. (3) With regard to data protection, the applicable data protection laws as well as the privacy policy of the respective social media are to be observed. For questions please contact: office@eanm.org

Spanish Group propose adjustments to the European nomogram – used to predict and identify patients with BCR at higher ri...
13/05/2025

Spanish Group propose adjustments to the European nomogram – used to predict and identify patients with BCR at higher risk for a positive PSMA PET/CT – resulting in an optimized selection of BCR patients who are candidates for PSMA PET/CT.
Link to the journal:
https://onlinelibrary.wiley.com/doi/10.1002/pros.24910

Prostate-specific membrane antigen (PSMA) PET/CT has been established as the standard imaging technique after biochemical recurrence (BCR) of prostate cancer (PCa). However, its availability is not widespread, thus, patient selection criteria are necessary.

A negative PSMA-PET is a better predictor of "metastasis-free survival" when compared to conventional imaging in patient...
13/05/2025

A negative PSMA-PET is a better predictor of "metastasis-free survival" when compared to conventional imaging in patients with biochemical recurrence after radical prostatectomy.

AUA 2025 advanced prostate cancer, prognostic implication of a negative PSMA PET, biochemical recurrence, radical prostatectomy, PSMA PET scan, radical prostatectomy.

13/05/2025

Zachary Klaassen interviews Pratik Kanabur about a presentation on the cost-effectiveness of zirconium-girentuximab PET imaging for small renal masses. Dr. Kanabur explains that current diagnostic imaging methods for small renal masses have limited sensitivity, leading to both overtreatment and unde...

07/05/2025

AUA 2025, metastatic castration resistant prostate cancer (mCRPC), PSMAfore Study, 177Lu-PSMA-617.

07/05/2025

New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.

07/05/2025

While PSMA PET/CT revealed an 87 percent local remission rate after metastasis-directed radiotherapy for oligometastatic prostate cancer in a new study, researchers also found that 80 percent of patients had biochemical progression at a median 32-month follow-up.

08/04/2025

[177Lu]Lu-prostate-specific membrane antigen (PSMA)–617 is a standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an androgen receptor pathway inhibitor. However, for many, responses are short and progression is inevitab...

08/04/2025

Metastasis-directed therapy (MDT) in oligometastatic renal cell carcinoma (RCC) is typically based on conventional imaging. Prostate-specific membrane antigen (PSMA) PET/CT has shown superiority over conventional imaging. Our objective was to perform a proof-of-concept study to evaluate the efficacy...

08/04/2025

PSMA and Beyond 2025 approved PSMA imaging agents, evolution of PSMA imaging agents, UCSF/UCLA 68Ga-PSMA-11 trial, OSPREY 18F-DCFPyL trial, LIGHTHOUSE 18F-rhPSMA 7.3 trial.

PSMA-guided metastasis directed therapy for oligometastatic Renal Cell Carcinoma - Results from the PEDESTAL study
01/04/2025

PSMA-guided metastasis directed therapy for oligometastatic Renal Cell Carcinoma - Results from the PEDESTAL study

Metastasis-directed therapy (MDT) in oligometastatic renal cell carcinoma (RCC) is typically based on conventional imaging. Prostate-specific membrane antigen (PSMA) PET/CT has shown superiority over conventional imaging. Our objective was to perform a proof-of-concept study to evaluate the efficacy...

FYI - FREE article published  (Feb 2025) regarding the relationship between the tumoral microenvironment and Radium-223....
03/03/2025

FYI - FREE article published (Feb 2025) regarding the relationship between the tumoral microenvironment and Radium-223.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11853176/

Radium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease. To better understand the action of 223Ra, its role in the tumor microenvironment represents a crucial aspect.

Adresse

Fünfhaus

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von EANM Oncology Committee erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Teilen